Clinical medicine profile
Atropine Sulphate (L-Hyoscyamine)
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Premedication: By I.V inj. 300-600mcg immediately before anesthesia. Dose increased by 100mcg for the treatment of bradycardia. Organophosphorus poisoning: I.M or I.V 2mg every 20-30mins until the skin becomes dry, the pupils dilate and tachycardia develops.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Drying of bronchial and salivary secretions due to inhalations in anesthetics and intubations
- prevention of the onset of bradycardia and other muscarinic action due to neostigmine
- diagnosis of sinus node dysfunction and in the evaluation of coronary artery disease during atrial pacing
- Organophosphorous poisoning as an antidote.
Adverse effects
- Dry mouth
- blurred vision
- cyclo-plegia
- mydriasis
- photophobia anhidrosis
- urinary hesitancy and retention
- tachycardia
- increased ocular tension
- loss of taste sensation
- headache
- nervousness
- drowsiness
- weakness
- dizziness
Drug interactions
Open multi-drug checker ↗- General notes: It is a classical antimuscarinic that is usually obtained by extraction from various members of the Solanaceae genus of plants including Atropa, Datura stramonium, or Duboisia myoporoides.
Mechanism & disposition
Prototype antimuscarinic agent.
Read complete mechanism
Prototype antimuscarinic agent. Precautions: Myasthenia gravis, renal and hepatic impairment, children, elderly, diarrhea, glaucoma, hypertension, ulcerative colitis, Downs syndrome.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.